Hypertension drug’s new label warns of SJS, TEN
A medication used for the management of hypertension now includes an updated safety label that warns patients of a rare but serious skin condition, according to the Food and Drug Administration (FDA)’s Safety Information and Adverse Event Reporting Program. The new safety label for Inderide (propranolol HCL/hydrochlorothiazide) tablets carries a warning of “erythema multiforme including Stevens Johnson Syndrome (SJS), exfoliative dermatitis, including toxic epidermal necrolysis (TEN)” in the Adverse Reactions section.